{"id":"W2901315913","doi":"10.1136/annrheumdis-2018-eular.2983","title":"AB0955 Tildrakizumab efficacy over time by week 28 response levels in two phase 3 clinical trials in patients with chronic plaque psoriasis","year":2018,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":2,"is_retracted":false,"has_abstract":false,"ca_institutions":"SKiN Health; Probity Medical Research","funders":"Sanofi Genzyme; Allergan; LEO Pharma; Astellas Pharma; Dermira; Regeneron Pharmaceuticals; Genentech; Valeant Pharmaceuticals International; Sanofi; Amgen; Pfizer; Active Biotech; Biogen; Celgene; AstraZeneca; Eli Lilly and Company; GlaxoSmithKline","keywords":"Medicine; Psoriasis Area and Severity Index; Plaque psoriasis; Placebo; Internal medicine; Psoriasis; Gastroenterology; Clinical trial; Randomized controlled trial; Dermatology; Pathology","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003400705,0.001147774,0.0026983,0.0005507292,0.0005552867,0.001115278,0.0005775479,0.0009708831,0.002732816],"category_scores_gemma":[0.001797057,0.0006270126,0.001994295,0.0004998918,0.0007590494,0.001034003,0.0004057677,0.002836233,0.0006356661],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008592767,"about_ca_system_score_gemma":0.0009732744,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008821759,"about_ca_topic_score_gemma":0.00232783,"domain_scores_codex":[0.998676,0.0005952732,0.0001237329,0.0002188101,0.0001342006,0.0002520598],"domain_scores_gemma":[0.998816,0.0003126291,0.0003192597,0.0001144867,0.0001048789,0.0003327336],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8059584,0.02550248,0.006821185,0.0008861886,0.001884487,0.0001139162,0.0003410347,0.001696715,0.0493307,0.000163957,0.001563841,0.1057371],"study_design_scores_gemma":[0.4047845,0.522786,0.05850711,0.00008776066,0.002056941,0.0002327004,0.0001508525,0.001489033,0.006617744,0.0002462924,0.002941932,0.00009913357],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9939143,0.003364981,0.0002643117,0.0002433345,0.0000797986,0.0007548378,0.0004453645,0.0000551726,0.0008778282],"genre_scores_gemma":[0.9948252,0.001335697,0.0007946818,0.0002555245,0.00008892907,0.001074239,0.0005514599,0.000019847,0.001054457],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003400705,"threshold_uncertainty_score":0.01798481,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0742742728827114,"score_gpt":0.389371472254729,"score_spread":0.3150971993720176,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}